

## Disclosures

### Personal Commercial (8)

| Company Name    | Relationship Category     | Compensation Level | Topic Area(s)                      |
|-----------------|---------------------------|--------------------|------------------------------------|
| <i>Self</i>     |                           |                    |                                    |
| biocontrol      | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| biotronik       | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| columbia/va     | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| corthera        | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| medtronic       | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| pfizer          | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology                 |
| pozen           | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| st jude medical | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

### Personal Non-Commercial (5)

| Non-Commercial Entity Name       | Relationship Category    | Compensation Level       | Topic Area(s)                      |
|----------------------------------|--------------------------|--------------------------|------------------------------------|
| <i>Self</i>                      |                          |                          |                                    |
| BMS<br>† gilead                  | Speaker's Bureau         | Modest (< \$5,000)       | General Cardiology                 |
| gilead<br>† boehringer-ingleheim | Speaker's Bureau         | Modest (< \$5,000)       | General Cardiology                 |
| N/A<br>† Cardioxyl               | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Otsuka                           | Speaker's Bureau         | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| SANOFI<br>† Sanofi-Aventis       | Speaker's Bureau         | Modest (< \$5,000)       | Arrhythmias and Clinical EP        |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

**Certified Education Attestation** | Signed on 3/1/2012

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 3/1/2012

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 3/1/2012

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 3/1/2012

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.